Crinetics Pharmaceuticals secured FDA approval for Palsonify (paltusotine), the first oral once-daily therapy for adults with acromegaly, an endocrine disorder caused by excess growth hormone. This priority review approval positions Crinetics to compete against established injectable treatments from Novartis and Ipsen. The oral formulation may offer improved convenience and adherence for patients with limited surgical options or inadequate response to surgery.